Dermatology
Atopy
More in Atopy
EASI-75 was achieved by majority of patients taking 15 mg or 30 mg at 76 weeks
38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks
More patients see treatment success with delgocitinib vs cream vehicle in two phase III trials
Over 90 days of exposure linked to adverse events
At highest dose, novel cendakimab hits primary endpoint in phase II study
Further study needed to explore link between skin sodium and autoimmune inflammatory conditions
An increased number of antibiotic courses corresponded to a dose-response-like increased risk
Association primarily limited to children with neurodevelopmental comorbidities
Urticaria severity reduced within weeks of treatment
No link between prenatal exposure and risk for autoimmune conditions, however
Our panel of experts discuss when might be the right time to reduce therapy
Our panel of experts discuss how they monitor patients on biologics and JAK inhibitors
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
We've got great treatments, says Steven Feldman, the key is getting patients to use them
